Sunesis Pharmaceuticals, Inc. (SNSS) Announces Participation in Cardiff University Sponsored Phase 2/3 Trial Evaluating Vosaroxin in Newly Diagnosed Elderly AML and High-Risk MDS Patients  
12/12/2011 9:52:42 AM

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2011 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced participation in a Phase 2/3 randomized, controlled, multicenter trial evaluating novel treatment regimens against low dose cytarabine (LD Ara-C), a commonly used treatment of elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). This trial, known as the Less Intensive 1 (LI-1) Study, is being conducted by the United Kingdom's National Cancer Research Institute (NCRI) Haematological Oncology Study Group under the direction of Professor Alan K. Burnett, Head of Haematology, Department of Medical Genetics, Haematology & Pathology at Cardiff University School of Medicine. Two regimens containing Sunesis' lead drug candidate, vosaroxin, have been selected as investigational treatment arms in this study.